Russain Direct Investment Fund (RDIF) is expecting to release the results of Sputnik V and Astrazeneca 'mix and match' vaccine by the end of July. In a press briefing, Krill Dmitriev, CEO, RDIF informed that high efficacy is expected from the trials. "This approach has been really pioneered by Sputnik V in the beginning. So we are open for mix and match a Covishield in India. We believe there will be a great result. Covishield is the same vaccine as Astrazeneca so we believe that trials will show high efficacy. We hope that the Serum Institute of India (SII) can produce Sputnik V and mix and match as well. It will be a true match as well. It will be a true partnership, "Said Dmitriey. The first batch of Sputnik vaccines is expected to be produced at SII's facilities in September, and both parties intend to produce over 300 million doses of the vaccine in India per year. "As part of the technology transfer process, SII has already received cell and vector samples from the Gamaleya Center. With their import approved by the Drug Controller General of India, the cultivation process has begun "Dmitriev said in a statement issued by RDIF. The Kerala girl who became India's first Covid patient after contracting the virus while studying medicine in China's Wuhan has tested positive again, this time at home. The Fourth year MBBS student is currently asymptomatic. She came to know about here reinfection only because of a mandatory RT-PCR test before proceeding to Delhi to collect some personal document that she had earlier submitted to the government. The girl, who had first tested positive on returning from Wuhan in the last week of January 2020, hasn't been vaccinated yet. Her father said she chose not to get the jab because she wanted to go back to China and wasn't sure whether any of the vaccines available in India would be accpeted there. In June, the company received regulatory approval to manufacture the Covid-19 vaccine, developed by Russia's Gamaleya institute and backed by RDIF.
